JP2013155195A5 - - Google Patents

Download PDF

Info

Publication number
JP2013155195A5
JP2013155195A5 JP2013099331A JP2013099331A JP2013155195A5 JP 2013155195 A5 JP2013155195 A5 JP 2013155195A5 JP 2013099331 A JP2013099331 A JP 2013099331A JP 2013099331 A JP2013099331 A JP 2013099331A JP 2013155195 A5 JP2013155195 A5 JP 2013155195A5
Authority
JP
Japan
Prior art keywords
amino acid
cysteine
peptide
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013099331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013155195A (ja
JP5764613B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013155195A publication Critical patent/JP2013155195A/ja
Publication of JP2013155195A5 publication Critical patent/JP2013155195A5/ja
Application granted granted Critical
Publication of JP5764613B2 publication Critical patent/JP5764613B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013099331A 2009-07-29 2013-05-09 副甲状腺ホルモンを低減する治療剤 Active JP5764613B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22969509P 2009-07-29 2009-07-29
US61/229,695 2009-07-29
US25581609P 2009-10-28 2009-10-28
US61/255,816 2009-10-28
US31363510P 2010-03-12 2010-03-12
US61/313,635 2010-03-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012523061A Division JP5270799B2 (ja) 2009-07-29 2010-07-29 副甲状腺ホルモンを低減する治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014023488A Division JP2014094967A (ja) 2009-07-29 2014-02-10 副甲状腺ホルモンを低減する治療剤

Publications (3)

Publication Number Publication Date
JP2013155195A JP2013155195A (ja) 2013-08-15
JP2013155195A5 true JP2013155195A5 (enExample) 2014-03-27
JP5764613B2 JP5764613B2 (ja) 2015-08-19

Family

ID=43527590

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012523061A Active JP5270799B2 (ja) 2009-07-29 2010-07-29 副甲状腺ホルモンを低減する治療剤
JP2013099331A Active JP5764613B2 (ja) 2009-07-29 2013-05-09 副甲状腺ホルモンを低減する治療剤
JP2014023488A Pending JP2014094967A (ja) 2009-07-29 2014-02-10 副甲状腺ホルモンを低減する治療剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012523061A Active JP5270799B2 (ja) 2009-07-29 2010-07-29 副甲状腺ホルモンを低減する治療剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014023488A Pending JP2014094967A (ja) 2009-07-29 2014-02-10 副甲状腺ホルモンを低減する治療剤

Country Status (29)

Country Link
US (11) US8999932B2 (enExample)
EP (5) EP4154900B1 (enExample)
JP (3) JP5270799B2 (enExample)
KR (1) KR101781841B1 (enExample)
CN (2) CN107674114B (enExample)
AU (1) AU2010278897B2 (enExample)
BR (1) BR112012002143B8 (enExample)
CA (1) CA2769525C (enExample)
CY (3) CY1118388T1 (enExample)
DK (2) DK2459208T3 (enExample)
ES (2) ES2607954T3 (enExample)
FR (1) FR17C1009I2 (enExample)
HR (2) HRP20161614T1 (enExample)
HU (3) HUE030960T2 (enExample)
IL (1) IL217749A (enExample)
LT (3) LT2459208T (enExample)
LU (1) LUC00008I2 (enExample)
MX (1) MX2012001213A (enExample)
NO (1) NO2017021I1 (enExample)
NZ (1) NZ597922A (enExample)
PL (2) PL2459208T3 (enExample)
PT (2) PT2459208T (enExample)
RU (1) RU2557654C3 (enExample)
SG (2) SG10201406921SA (enExample)
SI (2) SI2459208T1 (enExample)
SM (3) SMT201900307T1 (enExample)
TW (1) TWI520744B (enExample)
WO (1) WO2011014707A2 (enExample)
ZA (1) ZA201200726B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987200B2 (en) 2006-11-16 2015-03-24 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
EP4154900B1 (en) 2009-07-29 2024-08-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
WO2011108724A1 (ja) 2010-03-04 2011-09-09 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
ES2712048T3 (es) 2010-03-04 2019-05-09 Ea Pharma Co Ltd Derivado de alquilamina
WO2011118843A1 (ja) 2010-03-24 2011-09-29 味の素株式会社 グルタミン酸エステル誘導体又はその塩
EP2554165A4 (en) 2010-04-02 2014-04-30 Ajinomoto Kk PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS
LT2717896T (lt) * 2011-06-08 2017-02-27 Kai Pharmaceuticals, Inc. Terapiniai agentai, skirti fosforo koncentracijos serume reguliavimui
US20140315809A1 (en) * 2011-11-10 2014-10-23 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
US20150126457A1 (en) * 2012-04-17 2015-05-07 Brown University Neuroprotective composition and method of use
US20200354428A9 (en) 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
CN114376970A (zh) * 2013-06-28 2022-04-22 美国安进公司 Etelcalcetide (AMG 416)的稳定的液体制剂
US10407464B2 (en) * 2014-04-03 2019-09-10 Amgen Inc. Method for preparing AMG 416
CN105504012A (zh) * 2014-09-30 2016-04-20 深圳翰宇药业股份有限公司 一种多肽的制备方法
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US10858389B2 (en) 2015-03-26 2020-12-08 Amgen Inc. Solution phase method for preparing etelcalcetide
US9336841B1 (en) * 2015-04-16 2016-05-10 Taiwan Semiconductor Manufacturing Co., Ltd. Pipeline register with data alignment therein
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928320B (zh) 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
WO2018044468A1 (en) * 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM
WO2019092584A1 (en) * 2017-11-07 2019-05-16 Alphacore Pharma Llc Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms
TWI859130B (zh) 2017-12-20 2024-10-21 日商Ｅａ製藥股份有限公司 維持透析下之二次性副甲狀腺機能亢進症之預防或治療用醫藥組成物
KR101933685B1 (ko) * 2018-06-29 2018-12-28 주식회사 에스알바이오텍 약물이 코팅된 마이크로 니들 및 이의 제조방법
WO2020093069A1 (en) * 2018-11-02 2020-05-07 Ampersand Biopharmaceuticals, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers
JP7166309B2 (ja) 2019-04-03 2022-11-07 Ｅａファーマ株式会社 安定性の良好な医薬組成物
EP4021920A4 (en) 2019-08-26 2023-08-16 Auro Peptides LTD IMPROVED PROCESS FOR PRODUCTION OF ETELCALCETIDE HYDROCHLORIDE
CN118496313A (zh) * 2019-12-09 2024-08-16 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
WO2021226064A1 (en) * 2020-05-04 2021-11-11 University Of Louisville Research Foundation, Inc. Artificial intelligence-based systems and methods for dosing of pharmacologic agents
CN115087662B (zh) * 2020-09-10 2023-09-26 陕西麦科奥特科技有限公司 双特异性融合多肽化合物
US11359134B2 (en) 2020-10-19 2022-06-14 Saudi Arabian Oil Company Treatment fluids and methods for recovering hydrocarbons from a subterranean formation
EP4353248A4 (en) * 2021-06-08 2024-10-23 Beijing Tuo Jie Biopharmaceutical Co. Ltd. CALCIUM-SENSITIVE RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF
TW202313655A (zh) * 2021-06-08 2023-04-01 大陸商北京拓界生物醫藥科技有限公司 鈣敏感受體激動劑化合物的鹽酸鹽及醫藥組成物和其應用
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2025054169A1 (en) * 2023-09-05 2025-03-13 Wake Forest University Health Sciences Compositions and methods for topical treatment

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
WO1992008476A1 (en) * 1990-11-07 1992-05-29 The Scripps Research Institute Peptides that inhibit platelet binding of adhesion molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
AU3819497A (en) 1996-07-31 1998-02-20 General Hospital Corporation, The Novel parathyroid hormone-related peptide analogs
US5895368A (en) 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
WO1998033812A1 (en) * 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
SK151599A3 (en) * 1997-05-14 2000-09-12 Rhone Poulenc Rorer Pharma Peptide parathyroid hormone analogs
CA2291074C (en) * 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
JP2000336099A (ja) * 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びｃ型肝炎抗体検出用試薬
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US20020068342A1 (en) * 2000-02-09 2002-06-06 Rami Khosravi Novel nucleic acid and amino acid sequences and novel variants of alternative splicing
IL153378A0 (en) 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
DE10041126A1 (de) 2000-08-22 2002-04-04 Aventis Res & Tech Gmbh & Co DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
WO2002057413A2 (en) 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
AU2002240312A1 (en) 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
BRPI0207502B1 (pt) 2001-02-23 2018-10-09 Polyphor Ltd compostos, enanciômeros, composição farmacêutica, uso de compostos, e, processo para a fabricação de compostos
US6998404B2 (en) 2001-08-08 2006-02-14 Genomed, Llc Treatment or prevention of acute renal failure
AU2002335668A1 (en) 2001-08-08 2003-02-24 The Research Foundation Of The State University Of New York Muc7d1 peptides as antifungal and antibacterial agents
US7060023B2 (en) 2001-09-25 2006-06-13 The Foundry Inc. Pericardium reinforcing devices and methods of using them
US7037897B2 (en) * 2001-10-31 2006-05-02 Abbott Laboratories TRI-, TETRA-, and penta-peptides having antiangiogenic activity
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
WO2004039940A2 (en) 2002-05-14 2004-05-13 Bristol-Myers Squibb Company Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
EP1680446B1 (en) 2003-11-05 2007-10-31 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
EP1699813A2 (en) 2003-12-11 2006-09-13 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
WO2005072340A2 (en) 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
EP1781320A2 (en) * 2004-07-27 2007-05-09 Genzyme Corporation Use of thyrotropin for regeneration of bone
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
KR100687932B1 (ko) * 2005-08-09 2007-02-27 삼성전자주식회사 영상표시장치 및 영상표시방법
AU2006285127A1 (en) * 2005-08-30 2007-03-08 Acologix, Inc. Regulation of mineral and skeletal metabolism
US8987200B2 (en) * 2006-11-16 2015-03-24 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
AU2008206077A1 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
NZ584048A (en) * 2007-10-02 2012-08-31 Marina Biotech Inc Lipopeptides for delivery of nucleic acids
EP2229473A4 (en) 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
EP4154900B1 (en) * 2009-07-29 2024-08-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
LT2717896T (lt) 2011-06-08 2017-02-27 Kai Pharmaceuticals, Inc. Terapiniai agentai, skirti fosforo koncentracijos serume reguliavimui
US20140315809A1 (en) 2011-11-10 2014-10-23 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use

Similar Documents

Publication Publication Date Title
JP2013500990A5 (enExample)
RU2012107428A (ru) Терапевтические агенты для снижения уровней паратиреоидного гормона
US12496350B2 (en) Cyclic peptidyl inhibitors of CAL-PDZ binding domain
US12391733B2 (en) Stapled intracellular-targeting antimicrobial peptides to treat infection
JP2022514255A5 (enExample)
JP2013533864A5 (enExample)
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
EP1626055A3 (en) Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system
RU2014101697A (ru) Коагонисты рецепторов глюкагона/glp-1
CN102300580A (zh) 二肽连接的药剂
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
HRP20140616T1 (hr) Peptidni analog oksintomodulina
CN115244067A (zh) 合成抗微生物肽
JP2013537195A5 (ja) 疾患を治療するための医薬品及び同医薬品を含むキット
CA2968902C (en) Compounds derived from polymyxin
JP2011518179A5 (enExample)
JP2006514104A5 (enExample)
JP2004537581A5 (enExample)
JP2008514586A5 (enExample)
SK11242002A3 (sk) Zlúčenina, spôsob prípravy zlúčeniny, farmaceutický prostriedok a spôsob liečenia rakoviny
CN112672747B (zh) 用于激活骨祖细胞中细胞信号传导的肽
JP2012506408A5 (enExample)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2010536714A5 (enExample)
JP2007535910A5 (enExample)